Zycubo (copper histidinate)
Sentynl Therapeutics
ApprovedJan 12, 2026
Marketer take
The first FDA-approved treatment for Menkes disease, an ultra-rare pediatric copper disorder, so diagnosis in infancy and pediatric neurology and genetics referrals drive the launch.
- Sponsor company
- Sentynl Therapeutics
- Indication
- To treat Menkes disease
- Therapeutic area
- Rare disease
- Event
- FDA approval
- Date
- Jan 12, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?